Can-Fite Biopharma (CANF) vs Evogene (EVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evogene is the larger company by market cap ($6.3 million vs $6.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | EVGN |
|---|---|---|
| Share price | $2.00 | $0.3985 |
| Market cap | $6.06M | $6.30M |
| 1-day change | -4.76% | -2.95% |
| YTD return | -50.00% | — |
| 1-year return | -83.05% | — |
| 5-year return | -99.35% | — |
| EPS (TTM) | $-13.23 | $-1.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $1.49 |
| 52-week low | $1.96 | $0.35 |
| Distance from 52-week high | -83.87% | -73.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +300.00% | +439.52% |
| Average volume | 388.00K | 2.02M |
| Shares outstanding | 3.03M | 15.80M |
| Employees | 5 | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Healthcare · Biotechnology · 5 employees
About Evogene
EVGN stock →Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications.
Healthcare · Biotechnology · 38 employees
CANF vs EVGN FAQ
Which is bigger, Can-Fite Biopharma or Evogene?
Evogene (EVGN) is larger, with a market capitalization of $6.30M compared with $6.06M for Can-Fite Biopharma (CANF).
Are Can-Fite Biopharma and Evogene in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.